Mupirocin
FDA-approved product (ointment, topical), marketed as Bactroban, Centany, Mupirocin.
- Registered studies
- 50+
- Lab records
- 16
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Impetigo
- Infection
- Nasal congestion
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antibiotics for topical use; Other nasal preparations
- FDA pharmacologic class
- RNA Synthetase Inhibitor Antibacterial FDA label ↗
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC D06AX09; FDA class RNA Synthetase Inhibitor Antibacterial
Repurposing investigation
Mupirocin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA75.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli82.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae71.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 6 of 10 lab records
- E. coli: measured active in 1 of 2 lab records
- K. pneumoniae: measured active in 2 of 4 lab records
Show the 16 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Mupirocin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Detection, Education, Research and Decolonization Without Isolation in Long-term Care Facilities
NCT01302210 · start 2010-10
Registered record
- Registry ID
- NCT01302210
- Conditions
- Methicillin Resistant Staphylococcus Aureus
- Interventions
- Decolonization
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2010-10
- Completion
- 2014-11
- Enrolment
- 22,302
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMethicillin Resistant Staphylococcus AureusInterventionDecolonizationPhaseNot recordedRegistry statusCompletedEffect of Intranasal Mupirocin on Rate of Staphylococcus Aureus Surgical Site Infection Following Cesarean Sections
NCT01152593 · start 2010-07
Registered record
- Registry ID
- NCT01152593
- Conditions
- Surgical Wound Infection; Cesarean Section; Staphylococcus Aureus
- Interventions
- Mupirocin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2010-07
- Completion
- 2014-12
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSurgical Wound Infection; Cesarean Section; Staphylococcus AureusInterventionMupirocinPhaseNot applicableRegistry statusUnknownRisk of Methicillin-resistant S.Aureus (MRSA) Infections in MRSA Carrier Under Introduction of Rapid MRSA Screening
NCT01918813 · start 2009-11
Registered record
- Registry ID
- NCT01918813
- Conditions
- Inflammatory Bowel Disease; Hepatobiliary Disease; Pancreas Disease
- Interventions
- vancomycin, mupirocin ointment
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2009-11
- Completion
- 2012-02
- Enrolment
- 662
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammatory Bowel Disease; Hepatobiliary Disease; Pancreas DiseaseInterventionvancomycin, mupirocin ointmentPhaseNot applicableRegistry statusCompletedEpidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community
NCT00966446 · start 2009-09
Registered record
- Registry ID
- NCT00966446
- Conditions
- MRSA - Methicillin Resistant Staphylococcus Aureus Infection
- Interventions
- Unsupervised Decolonization; Supervised Decolonization
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2014-12
- Enrolment
- 223
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMRSA - Methicillin Resistant Staphylococcus Aureus InfectionInterventionUnsupervised Decolonization; Supervised DecolonizationPhaseNot applicableRegistry statusCompletedCluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)
NCT00980980 · start 2009-09
Registered record
- Registry ID
- NCT00980980
- Conditions
- Methicillin-resistant Staphylococcus Aureus
- Interventions
- Chlorhexidine bath and nasal mupirocin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2011-09
- Enrolment
- 74,256
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMethicillin-resistant Staphylococcus AureusInterventionChlorhexidine bath and nasal mupirocinPhaseNot applicableRegistry statusCompletedUnited States Pharmacovigilence Retapamulin-Prescribing
NCT01153880 · start 2008-12
Registered record
- Registry ID
- NCT01153880
- Conditions
- Skin Infections, Bacterial
- Interventions
- Retapamulin; Co-prescription of retapamulin and topical mupirocin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2008-12
- Completion
- 2012-08
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSkin Infections, BacterialInterventionRetapamulin; Co-prescription of retapamulin and topical mupirocinPhaseNot recordedRegistry statusCompletedTopical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis
NCT00751374 · start 2008-09
Registered record
- Registry ID
- NCT00751374
- Conditions
- Rate of Exit Site Infection; Rate of Atypical Mycobacterial Infection; Rate of Peritoneal Dialysis
- Interventions
- gentamicin; gentamicin cream alternating with mupirocin cream
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2008-09
- Completion
- 2014-10
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRate of Exit Site Infection; Rate of Atypical Mycobacterial Infection; Rate of Peritoneal DialysisInterventiongentamicin; gentamicin cream alternating with mupirocin creamPhasePhase 4Registry statusUnknownStaphylococcus Aureus Decolonization Study
NCT00731783 · start 2008-07
Registered record
- Registry ID
- NCT00731783
- Conditions
- Staphylococcal Skin Infections; Abscesses; Furunculosis; Staphylococcus Aureus; MRSA Infection
- Interventions
- 2% Mupirocin Ointment; 4% Chlorhexidine liquid soap; Hygiene protocol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2010-12
- Enrolment
- 183
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStaphylococcal Skin Infections; Abscesses; Furunculosis; Staphylococcus Aureus +1 moreIntervention2% Mupirocin Ointment; 4% Chlorhexidine liquid soap; Hygiene protocolPhaseNot applicableRegistry statusCompletedComparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx
NCT00713674 · start 2008-03
Registered record
- Registry ID
- NCT00713674
- Conditions
- Methicillin-Resistant Staphylococcus Aureus
- Interventions
- Theraworx; mupirocin antibiotic ointment
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Withdrawn
- Start
- 2008-03
- Completion
- 2009-02
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMethicillin-Resistant Staphylococcus AureusInterventionTheraworx; mupirocin antibiotic ointmentPhaseNot applicableRegistry statusWithdrawnA Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA
NCT00532324 · start 2008-02
Registered record
- Registry ID
- NCT00532324
- Conditions
- Staphylococcus Aureus
- Interventions
- CA-MRSA Decolonization
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2013-10
- Enrolment
- 107
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionStaphylococcus AureusInterventionCA-MRSA DecolonizationPhaseNot applicableRegistry statusCompletedEfficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
NCT00626795 · start 2008-02
Registered record
- Registry ID
- NCT00626795
- Conditions
- Impetigo; Secondarily Infected Traumatic Lesions
- Interventions
- TD1414 2% cream; TD1414 2% cream; Bactroban® (mupirocin) 2% cream
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2009-06
- Enrolment
- 773
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImpetigo; Secondarily Infected Traumatic LesionsInterventionTD1414 2% cream; TD1414 2% cream; Bactroban® (mupirocin) 2% creamPhasePhase 2Registry statusCompletedProspective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
NCT00631566 · start 2007-05
Registered record
- Registry ID
- NCT00631566
- Conditions
- HIV Infections; Staphylococcal Infections
- Interventions
- Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2007-05
- Completion
- 2017-10
- Enrolment
- 550
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; Staphylococcal InfectionsInterventionMupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%; PlaceboPhaseNot applicableRegistry statusCompletedA Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection
NCT00560599 · start 2007-04
Registered record
- Registry ID
- NCT00560599
- Conditions
- Methicillin Resistant Staphylococcus Aureus Skin Infections
- Interventions
- mupirocin and chlorhexidine; household cleaning and disinfection; mupirocin, chlorhexidine, & household cleaning/disinfection
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-04
- Completion
- 2012-12
- Enrolment
- 350
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMethicillin Resistant Staphylococcus Aureus Skin InfectionsInterventionmupirocin and chlorhexidine; household cleaning and disinfection; mupirocin, chlorhexidine, & household cleaning/disinfectionPhasePhase 3Registry statusCompletedThe Natural History of Community-Associated MRSA Infections and Decolonization Strategies
NCT00513799 · start 2007-03
Registered record
- Registry ID
- NCT00513799
- Conditions
- Abscesses; Furunculosis; Staphylococcus Aureus; Staphylococcal Skin Infections
- Interventions
- Mupirocin ointment; Chlorhexidine showers; Bleach baths (dilute); Intensive education on personal hygiene
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2010-12
- Enrolment
- 300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbscesses; Furunculosis; Staphylococcus Aureus; Staphylococcal Skin InfectionsInterventionMupirocin ointment; Chlorhexidine showers; Bleach baths (dilute); Intensive education on personal hygienePhaseNot applicableRegistry statusCompletedA Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections
NCT01049438 · start 2006-08
Registered record
- Registry ID
- NCT01049438
- Conditions
- Methicillin Resistant Staphylococcus Aureus Skin Infections
- Interventions
- nasal mupirocin; topical 3% hexachlorophene body wash; oral anti-MRSA antibiotic
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2006-08
- Completion
- 2009-09
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMethicillin Resistant Staphylococcus Aureus Skin InfectionsInterventionnasal mupirocin; topical 3% hexachlorophene body wash; oral anti-MRSA antibioticPhaseNot applicableRegistry statusCompleted